TBC1D20

Across TCGA pan-cancer cohorts, TBC1D20 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D20 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TBC1D20 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBC1D20 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where TBC1D20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	29	view →
PDAC	OS	Median	II,III,IV	0.619	0.355	.007	26	view →
LSCC	DFS	Quartile	II,III,IV	0.597	0.946	.004	11	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	3	view →
GBM	DFS	Tertile	All	0.815	0.634	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D20–CCRCC (DFS)

Open the CCRCC breakdown →